Head and neck squamous cell carcinoma
Conditions
Brief summary
Number of patients who had an objective response within 12 months
Detailed description
Progression events (loco-regional progression, metastatic progression or death whatever the cause) will be collected beyond 12 months of patient participation according to local practices., The patient's condition (alive, deceased from whatever cause or lost to follow-up) will be collected beyond 12 months of patient participation. Patients alive at the time of analysis will be censored on the date of last contact, Time from date of first documented response (complete or partial response) to date of first subsequent progression or death from any cause, Incidence of treatment-emergent adverse events, serious adverse events according to CTCAE V5.0 criteria and deaths, Taking the QLQ-C30 and QLQ-HN35 questionnaires
Interventions
DRUGsolution à diluer pour perfusion
DRUGErbitux 5 mg/mL solution for infusion
Sponsors
Centre Regional Lutte Contre Le Cancer
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients who had an objective response within 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression events (loco-regional progression, metastatic progression or death whatever the cause) will be collected beyond 12 months of patient participation according to local practices., The patient's condition (alive, deceased from whatever cause or lost to follow-up) will be collected beyond 12 months of patient participation. Patients alive at the time of analysis will be censored on the date of last contact, Time from date of first documented response (complete or partial response) to date of first subsequent progression or death from any cause, Incidence of treatment-emergent adverse events, serious adverse events according to CTCAE V5.0 criteria and deaths, Taking the QLQ-C30 and QLQ-HN35 questionnaires | — |
Countries
France
Outcome results
None listed